Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
暂无分享,去创建一个
T. Berg | O. Weiland | J. Rockstroh | U. Spengler | M. van der Valk | S. Zeuzem | H. Wedemeyer | P. Ferenci | M. Gschwantler | T. Welzel | J. Petersen | K. Herzer | Yue Zhao | M. Jiménez-Expósito | M. Peck‐Radosavljevic | T. Berg